Oncopeptides AB (ONCO) Stock Statistics & Valuation Metrics

Oncopeptides AB has a market cap or net worth of kr1.21B. The enterprise value is kr741.08M.

Oncopeptides AB has 211,263,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oncopeptides AB’s return on equity (ROE) is -5.24 and return on invested capital (ROIC) is -143.86%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Oncopeptides AB had revenue of 31.65M and earned -284.61M in profits. Earnings per share was -1.71.

In the last 12 months, operating cash flow was -261.52M and capital expenditures 0.00, giving a free cash flow of -261.52M billion.

Oncopeptides AB pays an annual dividend of ―, resulting in a dividend yield of ―

Oncopeptides AB upcoming earnings date is Aug 21, 2025, Before Open (Confirmed).

Oncopeptides AB as a current ratio of 4.23, with Debt / Equity ratio of -2026.13%

In the past 12 months, Oncopeptides AB has paid 398.00K in taxes.

Oncopeptides AB EV to EBITDA ratio is -0.72, with an EV/FCF ratio of -0.78.

Oncopeptides AB has kr107.22M in cash and marketable securities with kr118.39M in debt, giving a net cash position of kr11.16M billion.

Gross margin is 94.25%, with operating margin of -895.78%, and net profit margin of -899.29%.

The average price target for Oncopeptides AB is kr1.50, which is 11.43% higher than the current price. The consensus rating is Moderate Sell